Search results
Results from the WOW.Com Content Network
Cetuximab, sold under the brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer and head and neck cancer. [2] Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion .
Intravesical drug delivery through a urinary catheter. Intravesical drug delivery is the delivery of medications directly into the bladder by urinary catheter.This method of drug delivery is used to directly target diseases of the bladder such as interstitial cystitis and bladder cancer, but currently faces obstacles such as low drug retention time due to washing out with urine and issues with ...
It is administered by intravenous injection and is often prescribed in combination with radiotherapy or other chemotherapeutic regimens such as irinotecan. Since EGFR plays an essential role in maintaining skin integrity, one serious side effect of Cetuximab therapy is skin problems such as acne-like rash , skin drying and cracking due to the ...
Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. [1] It is an application of the fundamental research of cancer immunology (immuno-oncology) and a growing subspecialty of oncology.
Cetuximab: IV: EGFR inhibitor. Squamous cell head and neck cancer or EGFR-positive and KRAS wild-type metastatic colorectal cancer. Infusion-related reactions, skin reactions, hypomagnesaemia, hypocalcaemia, hypokalaemia, blood clots, interstitial lung disease and aseptic meningitis. Denosumab: SC: RANKL inhibitor.
myelosuppression, when administered prior to a platinum/etoposide or topotecan containing regimen for small cell lung cancer: Fosdenopterin: Origin Biosciences: molybdenum cofactor deficiency, Type A Tocilizumab: Genentech: systemic sclerosis-associated interstitial lung disease: Rilonacept: Kiniksa Pharmaceuticals: recurrent pericarditis ...
Neoadjuvant chemotherapy is given prior to a local treatment such as surgery, and is designed to shrink the primary tumor. [6]: 55–59 It is also given for cancers with a high risk of micrometastatic disease. [8]: 42 Adjuvant chemotherapy is given after a local treatment (radiotherapy or surgery). It can be used when there is little evidence ...
Uroflowmetry: Free uroflowmetry measures how fast the patient can empty his/her bladder. Pressure uroflowmetry again measures the rate of voiding, but with simultaneous assessment of bladder and rectal pressures. It helps demonstrate the reasons for difficulty in voiding, for example bladder muscle weakness or obstruction of the bladder outflow.